It's still a very small company and isn't looking for a buyout. The recent lawsuit against the top 3 companies didn't help, in addition to the red sea we have. I'm not concerned at all, when it becomes profitable and hospitals have to start using something other than traditional based op's this thing will really move.
I disagree. Management laid out their plan for the commercial launch of Dsuvia right after FDA approval. They are on schedule and in many cases ahead of the commercial launch outline they set forth during the investor day they held last December. Anyone doubting ACRX management team’s desire to create long term shareholder value has not followed the company for very long.
News 
Market Data 
Discover 
